Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ:ANGO)

8.560 -0.300 (-3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AngioDynamics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
Earnings Scheduled For January 8, 2025
 
Via Benzinga
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
In-Depth Examination Of 4 Analyst Recommendations For AngioDynamics
 
Via Benzinga
4 Analysts Assess AngioDynamics: What You Need To Know
 
Via Benzinga
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System
From AngioDynamics, Inc.
Via Business Wire
Limoneira And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
From AngioDynamics, Inc.
Via Business Wire
3 Stocks Insiders Are Buying Heavily In October 2024, And Why
Should investors add these stocks on their watchlist? Insider buys suggest so. 
Via Talk Markets
Nasdaq Moves Lower; Levi Strauss Shares Slide
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Crude Oil Jumps Over 4%; US Services PMI Revised Lower
 
Via Benzinga
Why AngioDynamics Stock Is Crashing Today
Investors didn't like the medical technology company's fiscal 2025 Q1 update. 
Via The Motley Fool
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
 
Via Benzinga
US Stocks Staring At Another Weak Open As Traders Await Key Jobs Report; Sentiment Wavers As Oil Extends Surge Amid Middle East Tensions
Sentiment continues to be cautious as traders play the “wait-and-watch” game until they see off Friday’s non-farm payroll data. The index futures traded moderately lower early Thursday. 
Via Benzinga
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings
 
Via Benzinga
S&P Settles Slightly Higher Despite Middle East Concerns: Fear Index Remains In 'Greed' Zone
 
Via Benzinga
Topics Stocks
Constellation Brands, Levi Strauss And 3 Stocks To Watch Heading Into Thursday
 
Via Benzinga
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
From AngioDynamics, Inc.
Via Business Wire
PDD Holdings, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
AngioDynamics to Participate in Upcoming Investor Conferences
From AngioDynamics, Inc.
Via Business Wire
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
 
Via Benzinga
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
AngioDynamics reported a Q4 2024 adjusted EPS loss of $(0.05), beating the consensus of $(0.16). Sales rose 1.9% to $79.1 million, driven by strong performance in the Med Tech segment. The company... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.